Parkinson’s disease is the second most common neurodegenerative disorder worldwide, affecting an estimated 11.7 million people, and its hallmark is the progressive death of dopamine-producing neurons in a brain region called the substantia nigra. That loss creates a dopamine deficit that underlies the tremors, stiffness, and slowed movement characteristic of the condition. The gold-standard treatment, levodopa, compensates for the missing dopamine but comes with long-term motor complications and ultimately depends on the survival of enough functional neurons to convert the drug into dopamine. This dependency has driven researchers to explore ways of boosting the brain’s own dopamine-manufacturing machinery instead.

The research team focused on two genes with complementary roles in that machinery. The first, DDC, encodes aromatic L-amino acid decarboxylase, the enzyme that chemically converts levodopa into dopamine. The second, GCH1, encodes GTP cyclohydrolase 1, the rate-limiting enzyme in producing tetrahydrobiopterin, an essential cofactor that tyrosine hydroxylase, the first enzyme in the dopamine synthesis pathway, cannot function without. Because these two genes sit at critical junctions of dopamine biosynthesis, the researchers reasoned that switching them on more strongly with CRISPR activation, or CRISPRa, might enhance the cell’s intrinsic capacity to produce dopamine.

Unlike conventional gene therapy, which delivers an extra copy of a gene packaged in a viral vector, CRISPRa works differently. It uses a catalytically inactive form of the Cas9 protein, called dCas9, fused to powerful transcriptional activator domains. Guide RNAs steer this complex to the promoter regions of target genes, where the attached activators recruit the cell’s own transcription machinery to boost gene expression from the native genomic location. Because no DNA is cut, the approach avoids the risks of double-strand breaks and avoids the capacity limits, immunogenicity, and manufacturing costs associated with viral vectors.

To test the concept, the team used two cell lines. Human embryonic kidney cells, or HEK293 cells, served as a robust, easily transfected non-neuronal comparison model. Human neuroblastoma SH-SY5Y cells, which display neuronal-like characteristics, were used to model Parkinsonian conditions. The researchers induced Parkinson-like toxicity in the SH-SY5Y cells by treating them with 6-hydroxydopamine, a neurotoxin that selectively damages dopaminergic neurons and is widely used to recreate features of the disease in laboratory settings. After this toxic exposure, they delivered the CRISPRa machinery.

The delivery system itself was notable for what it left out. Rather than using viral vectors or plasmid DNA, the researchers assembled the CRISPRa components as ribonucleoprotein complexes, combining dCas9-VP64 protein, an MS2-p65-HSF1 activator protein, and synthetic guide RNAs produced by in vitro transcription. These complexes were introduced into the cells using Lipofectamine 3000, a lipid-based transfection reagent. For DDC, a single guide RNA was used, while GCH1 was targeted with a dual-guide strategy aimed at both promoter and enhancer regions to maximize activation potential.

The results were revealing but tempered. In SH-SY5Y cells, CRISPRa targeting of DDC did produce a measurable increase in DDC gene expression relative to untreated controls, with statistically significant elevations at both 24 and 48 hours after transfection. However, when compared with the 6-OHDA-treated Parkinsonian control group, the CRISPRa-treated cells showed no significant difference in DDC expression. This means the neurotoxin itself had already altered DDC expression, making it impossible to clearly attribute the observed increase to CRISPRa activity rather than to the stress response triggered by 6-OHDA exposure.

GCH1 told a different story. Despite the dual-guide strategy targeting both promoter and enhancer regions, CRISPRa produced no significant increase in GCH1 expression in either cell line. The researchers noted that the overall analysis approached but did not reach statistical significance in SH-SY5Y cells, and they acknowledged that the small number of biological replicates in some groups, technical failures during quantitative PCR analysis, and possible limitations in delivery efficiency or chromatin accessibility at the target locus may all have contributed to the muted response.

On the safety front, the findings were more encouraging. In HEK293 cells, CRISPRa treatment had no significant effect on cell viability at either time point. In the Parkinsonian SH-SY5Y model, 6-OHDA significantly reduced viability compared with untreated controls, and the CRISPRa-treated groups showed similar reductions, but crucially, none of the CRISPRa-treated groups fared worse than the Parkinsonian control group. This suggests that the CRISPRa complexes themselves did not add toxicity beyond what the neurotoxin already caused.

The researchers are careful to frame these results as preliminary rather than definitive. They did not independently quantify transfection efficiency or confirm that the CRISPRa complexes successfully engaged their genomic targets, and they did not measure protein levels, enzyme activity, or actual dopamine production. Without those downstream validations, it remains unclear whether the modest transcriptional changes observed would translate into meaningful functional effects on dopamine biosynthesis. The team calls for future work incorporating non-targeting control guides, protein-level validation, enzymatic activity assays, direct dopamine measurements, and testing in more physiologically relevant models such as induced pluripotent stem cell-derived dopaminergic neurons before any conclusions about therapeutic potential can be drawn.

Subject of Research: CRISPR activation of dopamine biosynthesis genes DDC and GCH1 in cellular models of Parkinsonian neurotoxicity

Article Title: Assessment of the transcriptional and cellular effects of CRISPRa targeting Dopa decarboxylase and GTP cyclohydrolase 1 in HEK293 and SH-SY5Y cellular models of Parkinsonian neurotoxicity

Article References: Bhengu, S. Z., Singh, R., Ramsuran, V., & Msibi, Z. N. P. (2026). Assessment of the transcriptional and cellular effects of CRISPRa targeting Dopa decarboxylase and GTP cyclohydrolase 1 in HEK293 and SH-SY5Y cellular models of Parkinsonian neurotoxicity. Frontiers in Cellular Neuroscience, 20, Article 1883789. https://doi.org/10.3389/fncel.2026.1883789

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1883789

Keywords: CRISPRa, Parkinson's disease, DDC, GCH1, dopamine biosynthesis, SH-SY5Y cells, HEK293 cells, 6-hydroxydopamine, gene therapy, dCas9, neurodegeneration, transcriptional activation

The challenge the researchers faced is a classic one in modern biology. Single-cell RNA sequencing can measure how much every gene is expressed in thousands of individual cells at once, revealing which genes are noisy and which are consistently switched to the same level across a population. But a list of variable genes does not by itself reveal the proteins responsible for the variability. Hundreds of chromatin factors, transcription factors and RNA-processing proteins could, in principle, influence how steadily a gene is transcribed. Testing them all one by one would be prohibitively slow, so the team built an integrative computational pipeline designed to narrow the field before any experiment began.

The logic of the pipeline combines two kinds of genome-wide maps. The first comes from single-cell RNA sequencing of mouse embryonic stem cells, which quantifies transcriptional variability for each gene across the population. The second comes from chromatin immunoprecipitation sequencing, or ChIP-seq, datasets that record where candidate regulatory proteins physically bind across the genome. By overlaying these maps, the researchers could ask a targeted question: are the genes that show unusually high or unusually low expression variability preferentially bound by particular chromatin-associated proteins? If a protein’s binding sites are enriched near genes whose expression is especially stable, that protein becomes a candidate stabilizer; if its sites cluster near conspicuously noisy genes, it becomes a candidate destabilizer. This cross-referencing strategy turns scattered public datasets into a ranked shortlist of potential regulators of transcriptional noise.

Among the candidates that emerged from this screen, one stood out: Nucleosome Assembly Protein 1-Like 1, or NAP1L1. NAP1L1 belongs to the NAP1 family of histone chaperones, proteins that shuttle histones around the nucleus and help assemble nucleosomes, the spool-like structures around which DNA is wrapped. Because nucleosome organization directly shapes how accessible DNA is to the transcription machinery, a histone chaperone is a plausible lever on transcriptional consistency. The pipeline flagged NAP1L1 as a potential transcriptional stabilizer, meaning that its presence appeared to be associated with steadier gene expression in the stem cells.

To test this prediction directly, the team turned to a precision-targeting technique built on a deactivated form of the CRISPR-associated protein Cas9. In this approach, the DNA-cutting activity of Cas9 is disabled, but the protein retains its ability to be guided to a specific DNA sequence. The researchers fused NAP1L1 to this dCas9 scaffold and used guide RNAs to deliver the fusion protein to the promoter of Nanog, the gene whose noisy expression has made it a textbook example of transcriptional heterogeneity in stem cells. The result was striking: tethering NAP1L1 to the Nanog promoter stabilized NANOG expression in the cells. In other words, simply parking the histone chaperone at the gene’s control region was enough to reduce the cell-to-cell fluctuations that normally characterize this pluripotency factor, providing direct experimental evidence that NAP1L1 can act as a stabilizer at a specific locus.

A single-gene experiment, however, could not reveal whether NAP1L1’s influence is local or global. To address that question, the researchers generated embryonic stem cells in which the Nap1l1 gene was knocked out and compared them with wild-type cells using genome-wide single-cell transcriptomics. The comparison showed that loss of NAP1L1 increased transcriptional variability across the genome. Genes that had been expressed at consistent levels in the presence of the protein became noisier in its absence, supporting the idea that NAP1L1 plays a broad, global role in keeping transcription steady rather than merely fine-tuning one or two loci. This genome-wide view transforms the finding from an interesting observation about Nanog into evidence for a general mechanism of transcriptional stabilization in pluripotent cells.

With a functional role established, the next question was mechanistic: what does NAP1L1 actually do at the molecular level to smooth out transcription? To find its working partners, the team performed co-immunoprecipitation followed by mass spectrometry, a technique in which NAP1L1 is pulled out of cell extracts along with any proteins bound to it, and the captured molecules are then identified by their mass fingerprints. This experiment identified Developmental Pluripotency Associated 3, or DPPA3, as a key interacting partner of NAP1L1. DPPA3 is a protein associated with pluripotency and the germline, and its physical association with a histone chaperone suggests a plausible mechanistic basis for NAP1L1’s function: the two proteins may cooperate in organizing chromatin at variable genes, thereby influencing how reliably those genes are transcribed from cell to cell.

The significance of the work extends beyond one protein in one cell type. Transcriptional heterogeneity in embryonic stem cells is widely believed to be functionally important, priming individual cells toward different developmental fates and contributing to the plasticity that makes these cells so valuable for research and regenerative medicine. Yet the field has lacked a systematic framework for identifying the molecules that govern this heterogeneity. The integrative pipeline described in the study, which fuses single-cell expression data with chromatin binding maps, offers exactly that: a reusable recipe for discovering stabilizers and destabilizers of gene expression noise, complete with a published list of identified candidate regulators in the supplementary materials. Other laboratories can now apply the same strategy to different cell types, different developmental stages or different single-cell datasets to build a fuller catalogue of the noise-controlling machinery of the genome.

There are also broader implications for how scientists think about chromatin. Histone chaperones are usually discussed in terms of DNA replication and nucleosome assembly, housekeeping roles that keep the genome packaged correctly as cells divide. The new findings suggest that at least one member of this family has a more dynamic regulatory function, actively shaping the consistency of transcription in living stem cells. If NAP1L1 stabilizes expression by maintaining a favorable chromatin configuration at prone-to-fluctuate genes, then the balance between chromatin assembly and disassembly may be one of the fundamental determinants of how noisy a gene is, connecting the physical packaging of DNA to the probabilistic behavior of transcription that single-cell technologies have made visible.

The study, which was supported by the Israel Ministry of Science and by the European Union’s Horizon Europe programme under the EIC Pathfinder-Open grant RT-SuperES, was published open access in Genome Biology, with Tamar Segal, Elad Dvir, Matan Sorek, Amal Gharbi, Xue Sun, Michal Shoshkes-Carmel, Oren Ram and Eran Meshorer as authors. For now, the immediate takeaway is conceptual: the randomness observed in stem cell gene expression is not an uncontrolled byproduct of cellular life but a property with identifiable molecular guardians. NAP1L1, a histone chaperone recruited to the Nanog promoter through a CRISPR-based targeting system, demonstrably quiets transcriptional fluctuations, and its removal loosens the reins on gene expression across the genome. As researchers continue to dissect the NAP1L1-DPPA3 partnership and the other candidates surfaced by the new pipeline, the noisy inner life of the embryonic stem cell is likely to become considerably less mysterious.

Subject of Research: Regulation of transcriptional variability by the histone chaperone NAP1L1 in mouse embryonic stem cells

Article Title: Systematic discovery of potential regulators of transcriptional variability reveals NAP1L1 as a transcriptional stabilizer in mouse ESCs

Article References: Segal, T., Dvir, E., Sorek, M., Gharbi, A., Sun, X., Shoshkes-Carmel, M., Ram, O., & Meshorer, E. (2026). Systematic discovery of potential regulators of transcriptional variability reveals NAP1L1 as a transcriptional stabilizer in mouse ESCs. Genome Biology. https://doi.org/10.1186/s13059-026-04267-9

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04267-9

Keywords: embryonic stem cells, NAP1L1, DPPA3, transcriptional variability, pluripotency, Nanog, histone chaperone, single-cell RNA sequencing, ChIP-seq, dCas9, chromatin, Genome Biology

The central obstacle to a cure is the remarkable persistence architecture of the hepatitis B virus. After the virus enters hepatocytes through the NTCP receptor, its relaxed circular DNA genome is repaired by host factors into covalently closed circular DNA, or cccDNA, a stable episomal minichromosome that persists in the nucleus and serves as the transcriptional template for all viral RNAs and proteins. In parallel, fragments of viral DNA integrate at random sites into the host genome as integrated DNA, or intDNA, which does not produce new virus but continuously secretes surface antigen and, in some cases, the oncogenic HBx protein, fueling immune tolerance and carcinogenesis. Current interferon-alpha and nucleos(t)ide analog therapies leave both reservoirs untouched, so viral rebound is common once treatment stops, and long-term nucleos(t)ide therapy carries risks such as nephrotoxicity.

The Groningen team frames the therapeutic landscape around two epigenetic strategies. The first, broad-acting epidrugs, globally modulate histone- and DNA-modifying enzymes; nine such agents are already FDA-approved in oncology. The second, epigenetic editing, fuses effector enzymes to programmable DNA-binding domains — zinc-finger proteins, transcription activator-like effectors, or deactivated CRISPR-Cas9 — to write repressive marks at specific viral loci. Because HBV gene activity on cccDNA is governed by histone acetylation and methylation, with HBx recruiting p300 to boost H3 and H4 acetylation while SETDB1-mediated H3K9me3 and PRMT1-mediated H4R3 methylation repress transcription, the viral minichromosome is an unusually tractable epigenetic target.

Among epidrugs, sirtuin 2 inhibitors have produced the most compelling results. The SIRT2 inhibitor AGK2 reduced HBV DNA, RNA, HBsAg and HBeAg by 15 to 30 percent in vitro and in HBV-transgenic mice without hepatotoxicity, and recent work showed the drug acts by recruiting repressive histone lysine methyltransferases to cccDNA, enriching H4K20me1, H3K27me3 and H3K9me3 while reducing RNA polymerase II occupancy. A more specific allosteric inhibitor, FLS-359, blocked the conversion of rcDNA into cccDNA entirely in primary human hepatocytes when given before infection, cutting cccDNA formation by more than half — though it was ineffective after infection was established, positioning it as a preventive rather than curative agent. Meanwhile, the DNA methyltransferase inhibitor 5-azacytidine reactivated interferon-stimulated genes and sensitized otherwise unresponsive cells to interferon-alpha, but it also raised NTCP expression and HBsAg levels, highlighting the double-edged nature of globally acting agents.

That lack of locus specificity is precisely what epigenetic editing is designed to fix, and the review catalogs five preclinical editing studies organized around two approaches. Indirect editing directs a Krüppel-associated box, or KRAB, repressor domain to key HBV regulatory elements; KRAB acts as a scaffold recruiting histone deacetylases, lysine methyltransferases and heterochromatin proteins to shut down transcription. Direct editing instead guides DNA methyltransferases such as DNMT3a or the bacterial M.SssI enzyme to CpG islands overlapping viral promoters, writing de novo methylation that can be mitotically inherited. Both routes reduced HBV RNA, DNA and antigens from cccDNA and, in some contexts, from intDNA, with far better specificity than epidrugs.

The zinc-finger platform, the most rigorously studied to date, illustrates both the promise and the limits. Zhao and colleagues built a six-finger ZFP-KRAB artificial transcription factor targeting the X gene enhancer that cut HBx RNA by roughly 60 percent in Hep3B cells, a line carrying integrated viral DNA. Luo and colleagues achieved the most durable result, with HBV DNA falling to about one-third of control levels in transgenic mice by day seven and remaining significantly lower at day 28, although HBsAg was unchanged. The direct approach by Xirong and colleagues, fusing DNMT3a to a ZFP targeting the X promoter CpG island, lowered HBsAg by 58 percent in mice and 90 percent in cells, with confirmed methylation at seven CpG sites — but the effect reversed by day 20, likely through passive or TET-mediated demethylation. A single TALE-based study by Bloom and colleagues delivered the fastest repression, cutting HBsAg and HBV RNA by 80 percent in Huh7 cells within 48 hours and by 80 to 95 percent in mice within five days, though attribution to KRAB was complicated by the absence of a TALE-only control.

The dCas9 platform, which replaces costly protein engineering with inexpensive single-guide RNAs, is now moving fastest toward patients. The only peer-reviewed dCas9 data for HBV come from a doctoral thesis by Rendón, who fused M.SssI to dCas9 and targeted the conserved CpG islands adjacent to the C and S gene promoters, achieving 2 to 15 percent increases in methylation that downregulated C and S gene transcription but faded within 48 hours. Nevertheless, two clinical trials of dCas9 epigenetic editing for hepatitis B are already underway — NCT06745973 and NCT06671093 — and parallel successes silencing HIV provirus with dCas9-KRAB, plus the demonstration that combined KRAB and DNA methyltransferase editors such as CRISPRoff produce durable, heritable silencing, provide strong proof of concept. Notably, dCas9 editing avoids the genotoxicity risk that shadows nuclease-based CRISPR-Cas9 approaches, whose guide RNAs can partially match human genomic sequences and whose double-strand breaks at the many, variable intDNA loci raise off-target mutagenesis concerns.

Industry has now taken up the challenge with three programs. Tune Therapeutics’ Tune-401, a liver-targeting lipid nanoparticle carrying a guide RNA to CGI2 and mRNA encoding a dCas9 fused to a methyltransferase and an undisclosed repressor, reported 99.99 percent repression of cccDNA-derived HBV RNA in primary human hepatocytes, strong repression of RNA and HBsAg from intDNA in Hep3B cells, epigenetic marks persisting through 275 rounds of cell division over 550 days, minimal off-target effects by RNA-seq, and a favorable safety profile in non-human primates — though these results have not yet been peer reviewed. A Phase 1b trial is recruiting in Hong Kong, Moldova and New Zealand. EpiGENIC’s Epi-003, a similar LNP platform, has entered a Phase 1 trial in China, and nChroma Bio’s CRMA-1001 has shown greater than 99 percent HBsAg reduction sustained for six months in preclinical models. A related Omega Therapeutics trial using LNP-delivered ZFP editors in liver cancer further validates liver-directed epigenetic delivery.

Significant hurdles remain before any of this translates into a functional cure. HBV genomes differ by more than 8 percent at the nucleotide level across genotypes, and the error-prone reverse transcriptase plus the chaotic nature of integration create sequence variability that could blunt editing efficacy, demanding bioinformatic surveillance and possibly personalized designs. Heterochromatin spreading from KRAB editors could silence neighboring host genes at unpredictable intDNA sites, while complete silencing of all antigen sources raises the paradox that eliminating HBsAg might allow exhausted immune cells to miss residual infection, arguing for integration with immune-reactivation strategies. Model limitations compound the problem: primary human hepatocytes rarely form intDNA, Hep3B lacks infection dynamics, and the field needs 3D organoid and humanized mouse systems that capture both reservoirs. Cost and equity loom as well, since most patients live in Southeast Asia and Sub-Saharan Africa while comparable gene therapies have been priced near two million dollars. Still, the authors conclude that with optimized effector combinations, LNP-based hit-and-run delivery — already shown to sustain liver gene silencing for over a year in mice and over 90 days in non-human primates in PCSK9 studies — and clinically relevant models, precision epigenetic editing could deliver what nucleos(t)ide analogs never could: a stable, reversible, non-genotoxic functional cure for chronic hepatitis B.

Subject of Research: Epigenetic editing strategies to silence hepatitis B virus cccDNA and integrated DNA for a functional cure of chronic hepatitis B

Article Title: The promise of epigenetic editing strategies in functionally curing chronic hepatitis B virus infections

Article References: Fonseca, S. G., Cortés-Mancera, F. M., Rots, M. G., Sarno, F., & van der Laan, M. (2026). The promise of epigenetic editing strategies in functionally curing chronic hepatitis B virus infections. Epigenetics Communications, 6(1), Article 4. https://doi.org/10.1186/s43682-025-00041-3

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00041-3

Keywords: epigenetic editing, chronic hepatitis B, hepatitis B virus, cccDNA, integrated HBV DNA, dCas9, zinc-finger proteins, TALEs, KRAB, epidrugs, lipid nanoparticles, functional cure

The scale of methylation disruption in cancer is staggering. Tumor genomes characteristically display widespread global hypomethylation, in which vast stretches of normally methylated DNA lose their marks, accompanied by focal hypermethylation concentrated at key regulatory regions, particularly the CpG-rich promoters of tumor suppressor genes. The result is an extensive rewiring of gene regulatory networks: genes that restrain cell division are switched off, repetitive elements that are normally locked down become active, and the carefully orchestrated patterns that define cell identity dissolve into chaos. These alterations are so consistent that methylation signatures now underpin diagnostic and prognostic assays used in clinics worldwide, helping pathologists classify tumors, predict patient outcomes, and even trace the tissue of origin of metastatic cancers.

Yet a profound gap separates correlation from causation. The overwhelming majority of cancer-associated methylation changes have never been proven to drive tumor behavior; they may instead be passive consequences of the transformed state. Distinguishing driver marks from passenger marks using observational methylome profiling alone has proved remarkably difficult, because the epigenome is dynamic and context-dependent. This ambiguity has real consequences for drug development. Conventional hypomethylating agents, such as nucleoside analogs that trap and deplete methyltransferase enzymes, can partially reverse cancer-associated methylation alterations and have demonstrated clinical efficacy in selected hematological malignancies. But these drugs act genome-wide, with no capacity to target a specific promoter or enhancer. Their blunt mechanism limits both mechanistic insight—since any observed effect could stem from thousands of altered loci—and therapeutic precision, since desirable and undesirable demethylation occur simultaneously across the genome.

CRISPR-based epigenome editing offers a fundamentally different approach. Rather than cutting DNA, these systems repurpose catalytically inactive Cas proteins, most famously dCas9, as programmable delivery vehicles. Guided to a chosen genomic address by a complementary guide RNA, dCas9 can be fused to methylation ‘writers’—enzymes such as DNMT3A and DNMT3L that install methyl marks—or methylation ‘erasers’, including TET1 catalytic domains and engineered demethylases that oxidize and remove them. Because the underlying DNA sequence is left untouched, the editing is, in principle, reversible, mirroring the reversible nature of the epigenetic alterations themselves. The result is a technology capable of quantitatively tuning methylation at individual promoters, enhancers, and CpG shores—transition zones flanking CpG islands that are frequent sites of cancer-associated methylation gain.

The experimental power of this approach lies in its precision. A single tumor suppressor promoter can be hypermethylated in a controlled setting to test whether silencing of that gene is sufficient to confer growth advantages, or demethylated to ask whether restoring its expression suppresses malignant behavior. Similar logic applies to enhancers, whose methylation status can govern the activity of oncogenes and immune-modulatory genes alike. By editing specific loci, researchers can interrogate mechanisms of chemoresistance, asking whether methylation changes at particular drug-response genes cause treatment failure or merely accompany it. They can also probe immune modulation, since methylation patterns influence the expression of antigen-presenting molecules and immune checkpoint pathways that determine whether tumors are recognized by the immune system. In this way, methylation editing transforms the epigenome from a readout of tumor state into an experimentally addressable variable.

The review also highlights the modular nature of modern CRISPR recruitment platforms, which extend the technology well beyond simple enzyme fusions. Systems such as SunTag, MS2-based scaffolds, and related multiplexing strategies allow multiple effector domains to be recruited to a single target site, amplifying the magnitude of methylation change or combining writers and erasers with transcriptional activators and repressors. Such platforms enable graduated, quantitative manipulation of methylation levels rather than all-or-nothing switching, which is critical because the relationship between methylation density and gene expression is often dose-dependent. Combined with single-cell and multi-omics readouts, these tools allow researchers to observe how a targeted methylation edit propagates through chromatin state, transcription, and ultimately cellular phenotype in diverse cancer models, from cell lines to patient-derived organoids.

None of this progress comes without caveats, and the authors are candid about the obstacles that stand between bench and bedside. Off-target activity remains a central concern: both the DNA-binding specificity of guide RNAs and the promiscuity of the tethered enzymes can produce unintended methylation changes at sites resembling the intended target, and even at sites tethered transiently by direct enzyme-to-dCas9 fusions. Because methylation changes can be heritable through cell division, a single off-target event could have lasting consequences. Context-dependency poses a further complication. The same edit can yield different outcomes depending on chromatin context, cell type, CpG density, and the developmental or disease state of the cell, complicating efforts to generalize results across models. Delivery and durability add clinical dimensions to these challenges: getting large editing constructs efficiently into tumor cells—whether in culture or in a patient—and ensuring that the methylation change persists long enough to be therapeutically meaningful remain unsolved engineering problems.

The path forward, the review argues, lies in integration. Locus-specific editing is poised to converge with comprehensive multi-omics profiling, in which methylome, transcriptome, chromatin accessibility, and three-dimensional genome architecture are measured simultaneously before and after an edit. Machine-learning-guided target selection promises to accelerate this process, mining large epigenomic datasets to prioritize the methylation changes most likely to act as drivers, and to predict how editing a given locus will ripple through regulatory networks. Rational combination therapies represent the clinical endpoint of this vision: methylation editing might, for instance, be paired with immune checkpoint inhibitors by demethylating and reactivating antigen presentation genes, or with conventional chemotherapy by erasing methylation marks that drive drug resistance. Each of these strategies depends on the causal knowledge that only targeted editing can generate.

The significance of this synthesis extends beyond the technical details. For a generation, epigenetic therapy has been constrained by an uncomfortable irony: doctors could alter the cancer epigenome, but only in a coarse, genome-wide fashion that revealed little about which alterations mattered. CRISPR-based methylation editing inverts that logic, making the epigenome writable at single-locus resolution and thereby testable in a way no previous technology allowed. If the challenges of specificity, delivery, and context can be met, the result would be a new class of therapeutics that silence oncogenes or resurrect tumor suppressors without touching a single base of DNA sequence. For now, the technology’s greatest value is as an engine of discovery—a way to finally separate the drivers from the passengers in the cancer methylome. But the trajectory is clear, and the authors’ message is that rewriting the cancer epigenome has moved from metaphor to laboratory reality, with clinical translation as the next horizon.

One reason methylation is such an attractive target for editing is its intrinsic stability. Unlike histone modifications, which turn over rapidly and often require continuous reinforcement, DNA methylation at CpG sites can be faithfully copied through cell division by maintenance methyltransferases that recognize hemimethylated DNA after replication. This means a single, well-placed edit has the potential to persist across many generations of cells, a property that is both a strength for durable therapy and a liability if the wrong loci are modified. The review’s emphasis on precision reflects this double-edged character of the methylation mark.

The choice of effector enzymes also matters greatly. DNMT3A, one of the writer domains commonly fused to dCas9, is itself a gene frequently mutated in hematological malignancies, illustrating how the machinery of methylation regulation is intimately entangled with cancer biology. On the eraser side, catalytic domains derived from the TET enzymes, which normally initiate active demethylation through oxidation of 5-methylcytosine, can be repurposed for targeted removal of marks. That these same pathways are dysregulated in tumors underscores why locus-specific manipulation is such a valuable experimental tool: it allows individual components of an altered network to be tested in isolation.

The work emerges from a research group with a sustained focus on cancer epigenomics at the University of Otago’s Department of Pathology and Molecular Medicine, and the article is published open access under a Creative Commons Attribution license, supported by New Zealand funding bodies including the Health Research Council and the Marsden Fund. Open availability is significant for a methods-oriented review, since widespread adoption of these editing approaches depends on researchers across disciplines and resource settings being able to evaluate the technical trade-offs in detail.

It is also worth noting that the review appears at a moment when epigenome editing more broadly is maturing beyond proof-of-principle demonstrations. The same dCas9 recruitment logic underlies efforts to edit histone marks, chromatin architecture, and transcriptional states, suggesting that methylation editing will ultimately function as one module within a larger toolkit for writing and rewriting the regulatory layer of the genome.

Subject of Research: CRISPR-based DNA methylation editing technologies for interrogating and potentially treating aberrant cancer epigenomes

Article Title: Rewriting the cancer epigenome: CRISPR technologies for DNA methylation editing

Article References: Sadeghi, N., Rodger, E. J., & Chatterjee, A. (2026). Rewriting the cancer epigenome: CRISPR technologies for DNA methylation editing. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06429-1

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06429-1

Keywords: cancer, epigenetics, DNA methylation, CRISPR, DNA methylation editing, dCas9, epigenome editing, tumor suppressor genes, off-target effects, epigenetic therapy, gene regulation, precision medicine